N-803 immunotherapy may improve responses in BCG-unresponsive bladder cancer, advanced metastatic pancreatic cancer

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.

April 17, 2026

Vol.52 No.15

Drugs & Targets

FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC

FDA approved a label update that will accelerate thaw time for Adstiladrin (nadofaragene firadenovec-vncg), gene therapy for adults with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, enabling an accelerated water-bath thawing method, completed in about 25 minutes, to enhance efficient clinical preparation for healthcare teams.

March 27, 2026

Vol.52 No.12

Funding Opportunities

SITC seeks applications for two fellowships

Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding.

March 20, 2026

Vol.52 No.11

Guest Editorial

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

Nutrition therapy extends survival by 34% in stage 4 pancreatic cancer patients, clinical trial shows

Medically supervised, individualized nutrition therapy—long proven effective in reversing metabolic diseases like type 2 diabetes and obesity—shows promise in extending survival in patients with metastatic pancreatic cancer when used alongside chemotherapy, according to data from a randomized, controlled phase II clinical trial.

March 13, 2026

Vol.52 No.10

N-803 immunotherapy may improve responses in BCG-unresponsive bladder cancer, advanced metastatic pancreatic cancer

YOU MAY BE INTERESTED IN

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC

SITC seeks applications for two fellowships

As more people are surviving cancer, we must continue funding bold science

Nutrition therapy extends survival by 34% in stage 4 pancreatic cancer patients, clinical trial shows

Renew today!

Subscriber content

Never miss an issue!

Login

N-803 immunotherapy may improve responses in BCG-unresponsive bladder cancer, advanced metastatic pancreatic cancer

YOU MAY BE INTERESTED IN

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC

SITC seeks applications for two fellowships

As more people are surviving cancer, we must continue funding bold science

Nutrition therapy extends survival by 34% in stage 4 pancreatic cancer patients, clinical trial shows

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”